Prevalence of Obesity (Adults) Prevalence of Obesity (Children) CURRENT STRATEGIES IN. Obesity: 33.8% Men: 32.2% Women: 35.5%

Similar documents
NEW DEVELOPMENTS IN ASSESSMENT AND TREATMENT OF OBESITY

CURRENT STRATEGIES IN OBESITY

A SYSTEMATIC APPROACH TO

CURRENT STRATEGIES IN MANAGEMENT OF OBESITY. Prevalence of Obesity (Adults)

MANAGEMENT OF OBESITY: A

OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY

OBESITY: FACTS AND FICTIONS

UCSF Acknowledgments

Obesity Management in Women

Update in Obesity: the 10 Most Interesting Studies in DGIM Grand Rounds January 26, 2010

Bariatric Surgery: Indications and Ethical Concerns

Disclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None

11/11/2011. Bariatric Surgery for Sleep Apnea. Case Presentation: Rachelle. Case Presentation: Rachelle. Case Presentation: Rachelle

Disclosures. Obesity and Its Challenges: Outline. Outline 5/2/2013. Lan Vu, MD Division of Pediatric Surgery Department of Surgery

6/23/2011. Bariatric Surgery: What the Primary Care Provider Should Know. Case Presentation: Rachelle

SURGICAL MANAGEMENT OF OBESITY. Anne Lidor, MD, MPH Professor of Surgery Chief, Division of Minimally Invasive and Bariatric Surgery

Morbid Obesity A Curable Disease?

Weight Loss Surgery. Outline 3/30/12. What Every GI Nurse Needs to Know. Define Morbid Obesity & its Medical Consequences. Treatments for Obesity

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?

Lecture Goals. Body Mass Index. Obesity Definitions. Bariatric Surgery What the PCP Needs to Know 11/17/2009. Indications for bariatric Surgeries

Effect of Bariatric Surgery on Cardio-Metabolic Outcomes

Bariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018

Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.

10/28/11. Bariatric Surgery: What the Primary Care Provider Should Know. Case Presentation: Rachelle

Obesity and Bariatric Surgery Michel M. Murr, MD, FACS

A Bariatric Patient in my Waiting Room: Choosing the Right Patient for the Right Operation: Bariatric Surgery Indications

Overview of Management of Obesity

Overview. Stanley J. Rogers, MD, FACS Associate Clinical Professor of Surgery University of California San Francisco

Bariatric Surgery Update

Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD

10/16/2014. Normal Weight: BMI Overweight: BMI >25 Obese: BMI >30 Morbidly Obese: BMI >40 or >35 with 2 comorbidities

Bariatric Surgery Update

Surgical Therapy for Morbid Obesity. Janeen Jordan, PGY 5 Surgical Grand Rounds April 7, 2008

OBESITY IN PRIMARY CARE

OBESITY MANAGEMENT: DIET/EXERCISE, NEW DRUGS AND/OR SURGERY?

The New Trend of Anti-Obesity Drug

Not over when the surgery is done: surgical complications of obesity

OBESITY: The Growing Epidemic and its Medical Impact

The prevalence of obesity in adults has doubled over the past 30 years

Obesity D R. A I S H A H A L I E K H Z A I M Y

Viriato Fiallo, MD Ursula McMillian, MD

Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.

Treating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition

Gastrointestinal Surgery for Severe Obesity 2.0 Contact Hours Presented by: CEU Professor

OBESITY IN TYPE 2 DIABETES

13/09/2012. Therapeutic Options in Obesity. Clinical scenario (1) Clinical Symposium. Clinical scenario (2) Clinical scenario (3)

Obesity Management in Type 2 Diabetes

Faculty/Presenter Disclosure

Primary Outcome Results of DiRECT the Diabetes REmission Clinical Trial

Edward Melanson, Ph.D., Associate Professor, Division of Endocrinology, Metabolism, and Diabetes University of Colorado Denver

Conflict of Interest Disclosure Obesity Treatment: What Is a Staged Approach & What Does it Mean for Clinicians?

Obesity: Pharmacologic and Surgical Management

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

JAMA February 10, 2010 Laparoscopic Adjustable Banding in Severely Obese Adolescents: A Randomized Trial

ENTRY CRITERIA: C. Approved Comorbidities: Diabetes

APhA March 2016 Annual Meeting Obesity Cases

OBESITY:Pharmacotherapy Vs Surgery

Other Ways to Achieve Metabolic Control

You should try to lose some weight : an evidence- based approach to diet and weight loss Ridge Meadows Hospital Grand Rounds 14 September 2015

Bariatric Surgery. The Oregon Bariatric Center Surgical Team

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

The Obesity Epidemic: Its Impact in the Workplace and What Employers Can Do

10/29/2011. Metabolic, Obstetric, and Gynecological Consequences of Bariatric Surgery. Case Presentation: Rachelle. Jonathan Carter, MD

Understanding Obesity: The Causes, Effects, and Treatment Options

Current Trends in Bariatric Surgery

Bariatric Surgery: The Primary Care Approach

Case 1. Relationship Between Fat Free Mass and 24-hour Energy Expenditure

Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcomes

Jordan Garrison Jr. MD, FACS, FASMBS

How to Achieve Medical Weight Loss in 2012

Obesity Treatment Update

8/27/2012. Mississippi s Big Problem. An Epidemic Now Reaching Our Children. What Can We Do?

OBESITY AND WEIGHT LOSS SURGERY FOR THE PRIMARY CARE PHYSICIAN

Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD

The ABCDs of Obesity

Chairman s Rounds, 02/15/2011

No relevant financial relationships

Obesity and Bariatric Surgery

Policy Specific Section: April 14, 1970 June 28, 2013

Obesity and Weight Loss Surgery for the Primary Care Physician

Session 6B Appropriate Treatment of Obesity Demonstrates Clinical & Economic Success

Obesity Management. Ross M. Miller, MD, MPH

BASELINE TRAITS AS PREDICTORS OF SUCCESS IN MEDICAL WEIGHT MANAGEMENT

Current Management of Obesity

Americas Deadly Disease. Myths of how obesity came to be Eating food high in fructose, syrup, or a virus An epidemic disease

Diabetes Treatment Update

Bariatric Surgery. Options & Outcomes

Adjustable Gastric Band Surgery: Review of Current Practice. Dr. Chris Cobourn The Surgical Weight Loss Centre Mississauga, Ontario Canada

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Bariatric Surgery and Post Operative Patient Care Alisha M. Fuller DNP, CBN, FNP BC Tristate Bariatrics Clinical Director, NP Manager

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Benefits of Bariatric Surgery

Introduction Evidence-Based Guidelines

Adipocytes, Obesity, Bariatric Surgery and its Complications

What is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health.

Clinical Nutrition Center

Obesity Who is suitable for surgery? Professor Rob Andrews University of Exeter / Taunton NHS trust

Commonly Performed Bariatric Procedures in Singapore. Lin Jinlin Associate Consultant General, Upper GI and Bariatric Surgery Changi General Hospital

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Technique. Matthew Bettendorf, MD Essentia Health Duluth Clinic. Laparoscopic approach One 12mm port, Four 5mm ports

Transcription:

CURRENT STRATEGIES IN OBESITY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Prevalence of Obesity (Adults) Obesity: 33.8% Men: 32.2% Women: 35.5% Overweight + obesity: 68% Men: 72.3% Women: 64.1% Severe Obesity: 6% Flegal JAMA 2010 Men and Women Aged 40 to 59 Years in 1999-2000 and 2007-2008 Prevalence of Obesity (Children) Severe obesity (97 percentile): 11.9% Obesity (95 percentile): 16.9% Overweight (85 percentile): 31%. No increase from 1999 to 2008 (except severe obesity in boys) Flegal JAMA 2010 1

Obesity Disparities Women, 40-59 Black: 52%, Hispanic: 47%, Whites: 36% Teens Black: 29%, Hispanic: 17.5%, Whites: 14.5% Mental illness Overweight + obese: 83% For a 40 yo woman, which BMI is associated with the lowest allcause mortality? 1. 18 2. 24 3. 28 4. 34 5. 38 5% 52% 43% 0% 0% 18 24 28 34 38 Flegal JAMA 2010 CLASSIFICATION OF OVERWEIGHT AND OBESITY BY BMI Obesity Class BMI (kg/m 2 ) Underweight <18.5 Normal 18.5 24.9 Overweight 25.0 29.9 Obesity I 30.0 34.9 II 35.0 39.9 Extreme Obesity III >40 BMI AND MORTALITY: Overall Combined NHANES I, II, and III data set BMI 25-59 y 60-69 y 70 y <18.5 1.38 2.30 1.69 18.5-<25 1.00 1.00 1.00 25 to <30 0.83 0.95 0.91 30 to <35 1.20 1.13 1.03 35 1.83 1.63 1.17 Flegal, JAMA, 2005 2

Body Weight and Mortality Overweight (unlike obesity) is not associated with increased all cause mortality. It may be associated with decreased mortality. Overweight (like obesity) is associated with increased mortality from diabetes, but not from CV disease and cancer (unlike obesity) BMI AND MORTALITY: 19 studies and 1.46 Million White Adults. de Gonzalez, NEJM 2010 For a 40 yo woman, which BMI is associated with the lowest allcause mortality? 1. 18 2. 24 3. 28 4. 34 5. 38 Office-Based Screening and Communication Measure BMI at every visit Inform patients of BMI Non-judgementally compare to norms 3

Office-Based Screening and Communication Patients who are told they are overweight or obese: More likely to classify weight as health concern 60% US adults don t exercise regularly 25% are sedentary Epidemic of Inactivity Greater desire to lose weight More attempts to lose weight EXERCISE FOR OBESITY Meta-analysis analysis of 43 RCTs: 3476 participants Exercise plus diet vs diet alone -1.1 kg Increased intensity of exercise -1.5 kg Exercise without weight loss Reduced: BP, triglycerides, blood sugar Shaw, Cochrane, 2006 FITNESS AND MORTALITY Aerobics Center Longitudinal Study 25,714 men, 44 years old, 14 year observational study CV death (RR) normal overweight obese Fit 1.0 1.5 1.6 Not fit 3.1 4.5 5.0 Total death (RR) normal overweight obese Fit 1.0 1.1 1.1 Not fit 2.2 2.5 3.1 Wei, JAMA 1999 4

Relative Risk* of Death According to Body Mass and Physical Activity ** 1.00 Physical activity level 1.18 > 3.5 hours/week 1 3.4 hours/week < 1 hour/week 1.55 1.28 1.33 1.64 1.91 2.42 COMBINED AEROBIC AND RESISTANCE EXERCISE IN DIABETES (HART-D) 262 sedentary men and women (63%), Diabetes, HbA1c over 6.5% (average 7.7%) Four groups, 9 month study: Non-exercise Resistance training (3 days/week) Aerobics (12 kcal/kg/week) Aerobics (10 kcal/kg/week) plus resistance (2 days per week < 25 25 29.9 > 30 Body mass index (BMI) * RR s adjusted for age, smoking status, family history, menopausal status, hormone use, and other factors ** Reference group = women with 3.5 or > hours/week of physical activity and BMI of 25 or less Hu FB, et al. N Engl J Med 2004;351:2694 Outcomes: Hb A1c, fitness Church, JAMA 2010 COMBINED AEROBIC AND RESISTANCE EXERCISE IN DIABETES (HART-D) Control Resistance Aerobics Combined HbA1c 0.0-0.16-0.24-0.34* 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: V02 Max -0.03 + 0.1 + 0.6 +1.1* Weight (kg) + 0.4 +0.21-0.8-1.6* Waist circ (cm) +0.7-2.0* -1.6* -2.7* * p less.05 1. Meal replacement, very low calorie diet 2. Atkins Diets 3. South Beach Diet, Phase 1 4. Ornish Diet 5. All are contraindicated 6. None are contraindicated 6% 2% 4% 4% 12% 72% Church, JAMA 2010 Meal replaceme... Atkins Diets South Beach Di... Ornish Diet All are contra... None are contr... 5

COMPARISON OF WEIGHT LOSS DIETS WITH DIFFERENT MACRONUTRIENTS RCT of 811 patients, 4 diets: fat/protein/carbs 20/15/65; 20/25/55; 40/15/45; 40/25/35 6 months: 6kg, 7% weight; at 2 years: completers lost 4kg; 15% lost 10% of weight Results similar for: 15% pro v. 25% pro 20% fat v. 40% fat 35% carbs v. 65% carbs Heterogeneity of Response to Weight Loss Diets: Insulin Resistance Insulin sensitive: low carb and high carb both effective for weight loss Insulin resistant: low carb more effective Attendance highly correlated with weight loss; satiety, hunger, lipids, insulin all equal Sacks, NEJM, 2009 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: 1. Meal replacement, very low calorie diet 2 Atkins diet 3 South Bead Diet, phase 1 4. Ornish diet 5. All are contraindicated 6. None are contraindicated 6

Very Low Calorie Diets (VLCD) vs Low Calorie Diets (LCD): Meta-analysis analysis of 6 RCTs Trials with direct comparisons Short-term: mean 12.7 weeks Long-term: mean 1.9 years Weight loss (as % of initial weight): short-term long-term LCDs 9.7 5.0 VLCDs 16.1 6.3 (p) (0.001) (0.2) 40 yo woman, BMI 36. Much to your surprise (and satisfaction), she has lost 35 pounds. In order to maintain her new weight, her lifelong daily calorie intake should 48% be: 1. 2000 kcals 2. 1800 kcals 3. 1600 kcals 4. 1400 kcals 5. 1200 kcals 2% 35% 9% 6% Tsai and Wadden, Obesity, 2006 2000 kcals 1800 kcals 1600 kcals 1400 kcals 1200 kcals SUCCESSFUL WEIGHT LOSS MAINTENANCE 3000 subjects in National Weight Control Registry: 30-lb weight loss for 1-year Average weight loss 33 kg (10 BMI units less), average weight maintenance 5.5 years 45 years old, 80% women, 97% Caucasian 46% overweight as child, 46% one parent obese, 27% both parents SUCCESSFUL WEIGHT LOSS MAINTENANCE High levels of physical activity Women 2545 kcal/week, men 3293 kcal/week (1-hour moderate intensity per day Only 9% report no physical activity Diet low in fat, high in carbohydrate 1381 kcal day, 24% fat, 19% protein, 56% CHO 4.87 meals or snacks/day Fast food 0.74/week Regular self-monitoring of weight 44% weigh once per day; 31% once per week Wing, Am J Clin Nutr, 2005 Wing, Am J Clin Nutr, 2005 7

MACRONUTRIENTS AND WEIGHT MAINTENANCE RCT of 773 patients who had lost 8% of body weight, 26 weeks Comparison of 4 weight maintenance diets: low protein-low glycemic index, low protein-high glycemic index, high protein-low glycemic index, high protein-high glycemic index, Fewer drop outs with high protein-low glycemic index (26% vs 37% Less weight re-gain (-1kg): high protein vs low protein low glycemic index vs. high glycemic index 40 yo woman, BMI 36. Much to your surprise, she has lost 35 pounds. In order to maintain her new weight, her lifelong daily calorie intake should be: 1. 2000 kcals 2 1800 kcals 3 1600 kcals 4. 1400 kcals 5. 1200 kcals Larsen, NEJM, 2010 In the last year, I have prescribed a medication for weight loss. The medication I most commonly prescribe for weight loss is: 1. Yes 2. No 31% 69% 1. Phentermine 2. Sibutramine 3. Orlistat 4. Topiramate 5. Exenatide 6. Other 50% 15% 30% 5% 0% 0% Yes No Phentermine Sibutramine Orlistat Topiramate Exenatide Other 8

LONG TERM PHARMACOTHERAPY OF OBESITY Review of all RCT s more than 36 weeks published since 1960 Weight loss in excess of placebo: % of initial kg s Phen-fen 11.0% 9.6 kg Phentermine 8.1% 7.9 kg Sibutramine 5.0% 4.3 kg Orlistat 3.4% 3.4 kg Dexfenfluramine 3.0% 2.5 Kg Fluoxetine -0.4% -0.4 kg Diethyproprion -1.5% -1.5 kg The Neuroendocrinology of Energy Balance RIMONABANT Meta-analysis of 4 studies Rimonobant plus diet vs diet alone, for 1 year or more Rimonabant 20-4.9 kg loss (5%) Improved waist circ, BP, HDL, TG Attrition 40%: GI, psychiatric, neuro Rimonobant 5 mg -1.3 kg loss RIMONABANT June 2007 FDA advisory committee recommends that rimonabant not be sold in the US pending further study of depression and suicidality. Sanofi withdraws bid to sell rimonabant in US Curioni, Cochrane, 2006 9

SIBUTRAMINE AND CARDIOVASCULAR OUTCOMES (SCOUT) 9804 patients, over 55, with CV disease or diabetes Sibutramine vs. placebo, 3.4 year f/u Outcomes MI, stroke, cardiac arrest, CV death Results Weight: -1.7 kg BP: 1.2 vs 1.4 mm Hg Combined outcome: 11.4% vs. 10.0% (HR 1.16, p = 0.02) Nonfatal MI: 4.1% vs. 3.1% (HR 1.28; p = 0.02) Nonfatal Stroke: 2.6% vs 1.9% (HR 1.36; p = 0.03) Death: No differences James, NEJM 2010 Weight Loss Medications: October, 2010 Sibutramine (Meridia ): withdrawn by Abbott Increased risk of stroke and MI Lorcaserin (selective serotonin receptor agonist, more specific than fenfluramine): not approved by FDA Animals with increased mammary adenocarcinoma Phentermine/topiramate (Qnexa ): not approved by FDA Psychiatric adverse events: sleep, anxiety depression: 21% vs 10% with placebo Increased heart rate Teratogenicity OTHER INVESTIGATIONAL DRUGS Buproprion/zonisamide (Empatic ): Phase 3 Buproprion/naltrexone (Contrave ): Approved by FDA panel 12/10 Exenatide (Byetta ), Liraglutide (Victoza : Phase 2/3 Pramlintide/metreleptin: Phase 2/3 PRINCIPLES OF DRUG THERAPY NIH: BMI > 30 kg/m 2 or 27 kg/m 2 with co-morbidity (but in practice almost never) Motivated to begin structured exercise and low calorie diet Begin medications at completion of one month successful diet and exercise Continue medications only if additional weight loss achieved in first month with meds Cetilistat: Phase 3 in Japan 10

Wouldn t It Be Easier Just To Have Surgery? 57 yo woman, BMI 42 with diabetes, hypertension, and creatinine 1.4 asks about bariatric surgery. Her risk of mortality 30 days post-op is 1. 1 in 200 2. 1 in 100 3. 1 in 50 4. 1 in 25 5. 1 in 10 Bariatric Surgery and Mortality Swedish Obese Subjects Study 4047 subjects, surgery vs. matched control. 10.9 years f/u Max weight loss % Final weight loss % Control 2 Gastric bypass 32 25 Vertical banded Gastroplasty 25 16 Banding 20 14 Sjostrom, NEJM, 2007 % Resolution Comorbidity 100 90 80 70 60 50 40 30 20 10 0 Resolution of Comorbidities Bariatric Surgery A Systematic Review and Meta-analysis Buchwald H. et al. JAMA. 2004; 292(14):1724-37 Diabetes Hyperlipidemia HTN Sleep apnea Band VBG GBP D Switch 11

BARIATRIC SURGERY OUTCOMES: 2005-07 BARIATRIC SURGERY OUTCOMES: 2005-07 Ten sites, 4776 patients. 3/4 roux-en-y (87% lap); 1/4 lap band 30 Day overall mortality: 0.3% -lap band 0.0% -roux-en-y (lap) 0.2% -roux-en-y (open) 2.1% Composite (death, DVT, reintervention, 30 + days in hosp): 4.1% -lap band 1.0% -roux-en-y (lap) 4.8% -roux-en-y (open) 7.8% Predictors of poor outcomes: History of DVT or PE Obstructive sleep apnea Impaired functional status (can t walk 200 feet) Extremes of BMI (75 vs 53) Age, sex, race/ethnicity, other conditions were not LABS Consortium, NEJM, 2009 LABS Consortium, NEJM, 2009 COMPLICATIONS OF BARIATRIC SURGERY: EARLY Anastomotic leak 1-7% Stable line disruption 1.8% Gastric pouch dilation 1% DVT/PE 1.5% Anastomotic stricture 1.6-7% SBO/internal hernia 2-9% Cardiopulmonary failure 1.5% COMPLICATIONS OF BARIATRIC SURGERY: EARLY Marginal ulcer 1-13% Staple line hemorrhage 3% Subphrenic abcess 1% Wound: Infection 4.4% Hernia 3-25% Dehiscence 1% 12

SBO COMPLICATIONS OF BARIATRIC SURGERY: LATE Dumping Bile reflux Failed weight loss Nutrient Deficiencies B1 and B6 Pellagra, beriberi, Wernicke-Korsikoff Pernicious anemia (B12) Iron deficiency Calcium GASTRIC BANDING OR BYPASS Systematic review of 14 comparative studies (1 RCT) Roux-en Y gastric bypass associated with: More weight loss (76% vs. 48% excess weight) More resolution of co-morbidities (diabetes resolved 78% vs. 50%) More peri-op complications (9% vs 5%) Fewer re-operation rates (16% vs. 24%) Lab band associated with: Less OR time and shorter hospitalization Gastric bypass should remain the primary bariatric procedure Tice, Am J Med 2008 Weight Loss Before Bariatric Surgery Mortality Rate After Bariatric Surgery 881 patients with gastric bypass; 6 month program to achieve 10% weight loss; 2/3 lost 5%; 1/2 lost 10% Weight Change Complications % Gain 5% 28.4 Gain 0-5% 27.9 Loss 0-5% 23.5 Loss 6-10% 14.2 Loss 10% 18.0 (p for trend = 0.004) Benotti, Arch Surg, 2009 Flum, JAMA 2005. 13

57 yo woman, BMI 42 with diabetes, hypertension, and creatinine 1.4 asks about bariatric surgery. Her risk of mortality 30 days post-op is 1. 1 in 200 2. 1 in 100 3. 1 in 50 4. 1 in 25 5. 1 in 10 Bariatric Surgery and Mortality Swedish Obese Subjects Study Deaths HR Rate MI deaths Cancer deaths Control 129 0.063 25 47 Surgery 101 0.76 0.050 13 29 (p = 0.04) NNT 77 over 11 years (approx 850 per year) Sjostrom, NEJM, 2007 GOALS OF MANAGEMENT The Magic Formula Be as fit as possible at current weight Prevent further weight gain If successful at 1 and 2, begin weight loss 14